-
TOP10 sales in Beijing, Shanghai and Guangzhou are released!
Time of Update: 2021-11-05
Anti-tumor drugs are still the main drug in the three cities of Beijing, Shanghai and Guangzhou; Lipitor has grown against the trend, lung cancer star drugs have declined for the first time, and the sales of the three major brands have doubled; Zhu, CSPC, Qilu, Yangtze River.
-
CSPC will win $9 billion star anticoagulant
Time of Update: 2021-11-05
In 2020, Bristol-Myers Squibb’s Eliquis global sales exceeded 9 billion U.
In 2020, Bristol-Myers Squibb's Eliquis (apixaban tablets) global sales exceeded 9.
Bristol-Myers Squibb Eliquis global sales (unit: million dollars)Source: Mynet.
-
391 pharmaceutical companies posted their transcripts for the first half of the year!
Time of Update: 2021-11-05
have also reached new highs; 13 companies such as Zhifei Bio, Mindray Medical, and Hengrui Medical The profit exceeded 2 billion yuan; the gross profit margin of 18 companies including Ellis, Biotech, and Wuwu Biotech exceeded 90% .
-
Phase 3 clinical results of C3 complement inhibitors for the treatment of age-related macular degeneration released
Time of Update: 2021-11-05
On September 9, Apellis announced the top-line results obtained in two phase 3 clinical trials, DERBY and OAKS, in the research pegcetacoplan targeting the complement C3 protein .
com/news-release/2021/09/09/2294782/0/en/Apellis-Announces-Top-Line-Results-from-Phase-3-DERBY-and-OAKS-Studies-in-Geographic-Atrophy-GA -and-Plans-to-Submit-NDA-to-FDA-in-the-First-Half-of-2022.
-
Kelun Pharmaceutical's Ceftazidime/5% Glucose Injection was approved for drug registration
Time of Update: 2021-11-05
On September 28, Kelun Pharmaceutical issued an announcement stating that its subsidiary Hunan Kelun Pharmaceutical’s chemical drug "Ceftazidime for Injection/5% Glucose Injection" has recently been approved for drug registration by the National Medical Products Administration.
-
JAK inhibitor gets FDA approval again to treat fatal complications of stem cell transplantation
Time of Update: 2021-11-05
Today, Incyte announced that the US FDA has approved its JAK inhibitor Jakafi (ruxolitinib) to expand its indications for the treatment of chronic graft-versus-host disease (GVHD) adults and children over 12 years old .
-
Promote "what can be done" and crack the "can't be done" where does confidence in Chinese medicine come from
Time of Update: 2021-11-05
In the inheritance and development of more than two thousand years, traditional Chinese medicine has created world-renowned achievements, formed a systematic and complete scientific theory, and establ
-
Characteristics of the Japanese drugstore market: oligopoly, professionalism and convenience
Time of Update: 2021-11-05
Under this business logic, the development strategy of drugstores is more biased towards large and medium-sized convenience stores, with the main features of attracting young and middle-aged women in business districts and the elderly in the community .
-
Novavax submits emergency use application to WHO
Time of Update: 2021-11-05
(NASDAQ: NVAX), a biotechnology company dedicated to the development and commercialization of next-generation vaccines for severe infectious diseases, cooperates with it Partner Serum Institute of India Private Limited (SII) announced today that the two companies have submitted relevant regulatory documents to the World Health Organization (WHO) to apply for Novavax recombinant nanoparticle protein new coronary pneumonia vaccine candidates using Matrix-M™ adjuvant.
-
Novo Nordisk reached a settlement for $100 million in shareholder class action insulin pricing opaque
Time of Update: 2021-11-05
CompilationAspirinOn September 24, 2021, in a 2017 lawsuit filed in the Federal District Court of New Jersey after shareholders claimed that the insulin pricing disclosed by them was opaque, Novo Nordisk agreed to pay the plaintiff a settlement agreement of US$100 million .
-
Next-generation LPA1 antagonist Bristol-Myers Squibb Class 1 new drug approved for clinical use in China
Time of Update: 2021-11-05
ArticleMedicine GuanlanAccording to the latest announcement on the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, the Class 1 new drug BMS-986278-01, declared by Bristol-Myers Squibb Company (BMS), has been approved for two clinical trials in China, with special indications.
-
Talking about FGFR Inhibitors from the Combination Mode
Time of Update: 2021-11-05
From the eutectic structure with FGFR1 (Figure 2 right), it can be found that the dimethoxybenzene ring of PD173074 occupies the hydrophobic pocket in the ATP binding pocket through van der Waals interaction, and one of the methoxy groups forms a hydrogen bond with Asp641 .
-
Hengrui introduces the third-generation anti-CD20 monoclonal antibody of Tianguangshi Biology for a US$30 million equity investment
Time of Update: 2021-11-05
The two parties reached an agreement, and Tianguangshi Biotech granted Hengrui Pharmaceutical the exclusive commercialization rights for the third-generation anti-CD20 antibody MIL62 in the Greater China region (including Mainland China, Taiwan, Hong Kong, and Macau).
-
Green Valley Pharmaceuticals Holds Double Ninth Festival Caring Activities and Joins Hands with Various Parties to Create a Cognitive Impairment Friendly Environment
Time of Update: 2021-11-05
On October 13, a caring activity for patients with Alzheimer's disease called "Remember Memories, Eat Taste" kicked off in the "Green Memory Canteen" at the headquarters of Green Valley Pharmaceuticals, 10 people with mild cognition Elderly people with disabilities were invited to the scene to make Chongyang cakes with company employees and participate in the Jiujiu Memory Garden Party.
-
The next new 1 billion injection will be born and Osaikang will enter the game strongly
Time of Update: 2021-11-05
Figure 2: Sales of Roxatidine Hydrochloride Acetate for Injection (Unit: Ten Thousand Yuan)Source: Mi Nei. com, China's public medical institutions terminal competition patternAccording to data from Menet.
-
Yiling Pharmaceutical's Yishen Yangxin Anshen Tablets obtained drug registration certificate
Time of Update: 2021-11-05
Up to now, the company has invested about 26 million yuan in the research and development of the Yishen Yangxin Anshen Tablet project .
-
Shanghai Pharmaceuticals: Caffeine Citrate Injection was approved for production
Time of Update: 2021-11-05
On September 13, Shanghai Pharmaceuticals issued an announcement stating that the caffeine citrate injection of its subsidiary, Shanghai Hefeng, received the "Drug Registration Certificate" issued by the State Drug Administration, and the drug was approved for production .
-
STSA-1005 injection, a wholly-owned subsidiary of Shutaishen, obtained clinical trial approval from the U.S. FDA
Time of Update: 2021-11-05
STSA-1005 specifically binds to human GMRα and blocks its interaction with the ligand GM-CSF, thereby negatively regulating the innate immune response .
STSA-1005 injection is independently developed by the company's wholly-owned subsidiary Stadson BioPharma Inc.
-
Yangtze River's big move?
Time of Update: 2021-11-05
Currently, 15 innovative drugs (14 are category 1 new drugs) are in the clinical application and above stage; 79 have been reviewed The varieties (22 are the first ones) are eye-catching, helping the company to harvest a lot in centralized procurement; 76 new classifications are under review, and 20 have not been approved for the first copy .
-
The Gan-Shaan Union Central Procurement Quotation Decrypts 28 Drugs from 25 Enterprises Enters the Second Bargaining
Time of Update: 2021-11-05
From the rules of selection:If the number of declared companies is 1, the expert group negotiates to produce the result of the selection.
The applying enterprise makes a second quotation, and the expert group negotiates the final selected enterprise .
